Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of the combination of Tenghuangjiangu tablets, alfacalcidol capsules and caltrate D3 tablets in osteoporotic vertebral compression fracture, and their effects on bone metabolic indices

Xianbin Duan, Bi Liu, Xiaohu Lu

Department of Orthopedics, Shenzhen People's Hospital, 3046 Shennan East Road, Luohu District, Shenzhen, Guangdong 518000, China;

For correspondence:- Xiaohu Lu Email: Xiaohu_lu@medicine-edu.cn Tel:+8675525533018

Accepted: 3 October 2022 Published: 28 October 2022

Citation: Duan X, Liu B, Lu X. Efficacy of the combination of Tenghuangjiangu tablets, alfacalcidol capsules and caltrate D3 tablets in osteoporotic vertebral compression fracture, and their effects on bone metabolic indices. Trop J Pharm Res 2022; 21(10):2175-2181 doi: 10.4314/tjpr.v21i10.19

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of the combination of Tenghuangjiangu tablets, Alfacalcidol capsules and Caltrate D3 tablets in osteoporotic vertebral compression fracture (OVCF) and their effects on bone metabolic indices.

Methods: Ninety-six patients with OVCF were randomly categorized into study group (SG) and control group (CG). Patients in the CG orally took Caltrate D3 tablets, while those in the SG were given Tenghuangjiangu tablets and Alfacalcidol capsules in addition to caltrate D3 tablets. The Bone mineral density (BMD) values and the treatment efficacy were compared. The levels of bone metabolism markers (PINP, β-CTX, BGP, NBAP), CT and PTH were determined using electrochemiluminescence immunoassay, while Ca²⁺ levels were assessed using liquid level detection. The incidence of adverse reactions (re-fracture, gastrointestinal reaction, hypotension and abnormal coagulation function) were compared.

Results: Treatment efficacy in the SG was 91.67 %, which was significantly higher than that in the CG (81.25 %; p < 0.05). Before treatment, the two groups showed no significant differences in BMD, PINP, β-CTX, BGP, NBAP, Ca²⁺, CT, and PTH levels (p > 0.05). After treatment, the SG exhibited significantly higher BMD, PINP, BGP, NBAP, Ca²⁺ and CT levels, and showed lower β-CTX and PTH levels than the CG (p < 0.05). The SG exhibited a significantly lower incidence rate of adverse reactions than that the CG (p < 0.05).

Conclusion: The combination of Tenghuangjiangu tablets, Alfacalcidol capsules, and Caltrate D3 tablets, improves bone metabolic indices, bone density and treatment efficacy while reducing the incidence rate of adverse reactions.

Keywords: Tenghuangjiangu tablets, Alfacalcidol, Caltrate D3 tablets, Osteoporotic spine fracture